Companies
FDA accepts Intellia’s lonvo-z BLA for HAE with Priority Review
The agency set a March 10, 2027 target action date for the application, supported by Phase 3 HAELO results. Acceptance does not constitute approval.
Search stocks, ETFs and companies
Verified identity
Start with the filing record
The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.
- Ticker
- NTLA
- CIK
- 0001652130
- Exchange
- Nasdaq
- Universe updated
- 2026-08-22
Market price
Market price
Latest quoteOpens Google
TickerGrove coverage
Latest on Intellia Therapeutics, Inc.
Research foundation
Read the filing with the right frame
Company analysis
Revenue, EPS and guidance answer different earnings questions
Revenue is the top-line amount recognized from a company’s activities under its accounting policy.
Company analysis
The three financial statements describe one business from different angles
The income statement records revenue and expenses over a period.
Investing basics
Stocks, ETFs and indexes are different objects
A stock is an ownership interest in one company.